J&J Nabs Option to Buy In Vivo CAR-T Maker Sail for Nearly $2.6B
Deals·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
The deal with the buzzy Flagship Pioneering-backed startup could total nearly $2.6 billion.
Johnson & JohnsonSail Biomedicines
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B“Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.<br>”
fierce biotech — <a href="/biotech/jj-pays-sail-785m-charting-course-possible-vivo-car-t-buyout" hreflang="en">J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout</a>